

HCV Treatment Uptake Patterns in New South Wales, Australia: A Contemporary Analysis of the Advanced DAA Era

Shane Tillakeratne | Viral Hepatitis Clinical Research Program | Kirby Institute
University of New South Wales, Sydney, Australia

Prof. Gregory J. Dore

Prof. Sallie-Anne Pearson

Dr. Maryam Alavi

Dr. Heather Valerio

WHO aims to eliminate viral hepatitis as a major public health threat by 2030

DAA revolution in Australia:

- Direct-acting antivirals transformed HCV treatment since 2016
- High cure rates (>95%) with shorter, better-tolerated regimens
- Pangenotypic formulations available from 2019

Research gap:

- Limited data on treatment initiation timing post-notification
- Need to understand disparities in the advanced DAA era



Question

1. Has treatment uptake timeliness improved between the **early DAA era** (2016-2018) and **pangenotypic DAA era** (2019-2021) in NSW?
2. What **factors** are associated with **treatment initiation** following **HCV notification** during the **DAA era** (2016-2021) NSW?




UNSW
Kirby Institute




UNSW
SYDNEY

Method


Data linkage






Time to treatment

Time to treatment curve comparing the proportion of DAA treatment among people with an HCV notification in NSW 2016-2018 and 2019-2021.



Logistic Regression Model

Factors associated with treatment within 6 months among people with HCV notification in NSW, 2016-2021



Findings

Key Findings

Highlights

- Improving treatment timeliness in NSW

Challenges

- Potential treatment gaps among people with coinfection, AUD

End

Thank you.